Article
Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.
American journal of hematology - 1 Feb 2023
Gangat Naseema, Begna Kebede H, Al-Kali Aref, Hogan William, Litzow Mark, Pardanani Animesh, Tefferi Ayalew
Abstract excerpt
We retrospectively reviewed 72 anemic patients with myelofibrosis (MF; median age 68 years), who were JAK2 inhibitor-naïve at the time of study entry to a phase-1/2 momelotinib clinical trial. Driver mutation profile included JAK2 69%, CALR 17%, MPL 8%, and triple-negative 6%; other mutations included ASXL1 39% and SRSF2 17%. Momelotinib was administered at a median dose of 300 mg daily. Anemia response was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.